430 related articles for article (PubMed ID: 17478733)
1. Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins.
Tammela T; He Y; Lyytikkä J; Jeltsch M; Markkanen J; Pajusola K; Ylä-Herttuala S; Alitalo K
Circ Res; 2007 May; 100(10):1468-75. PubMed ID: 17478733
[TBL] [Abstract][Full Text] [Related]
2. Enhanced capillary formation stimulated by a chimeric vascular endothelial growth factor/vascular endothelial growth factor-C silk domain fusion protein.
Keskitalo S; Tammela T; Lyytikka J; Karpanen T; Jeltsch M; Markkanen J; Yla-Herttuala S; Alitalo K
Circ Res; 2007 May; 100(10):1460-7. PubMed ID: 17478734
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability.
Cao R; Eriksson A; Kubo H; Alitalo K; Cao Y; Thyberg J
Circ Res; 2004 Mar; 94(5):664-70. PubMed ID: 14739162
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor-C secreted by pancreatic cancer cell line promotes lymphatic endothelial cell migration in an in vitro model of tumor lymphangiogenesis.
Ochi N; Matsuo Y; Sawai H; Yasuda A; Takahashi H; Sato M; Funahashi H; Okada Y; Manabe T
Pancreas; 2007 May; 34(4):444-51. PubMed ID: 17446844
[TBL] [Abstract][Full Text] [Related]
5. Molecular control of lymphatic metastasis.
Achen MG; Stacker SA
Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
[TBL] [Abstract][Full Text] [Related]
6. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D.
McColl BK; Baldwin ME; Roufail S; Freeman C; Moritz RL; Simpson RJ; Alitalo K; Stacker SA; Achen MG
J Exp Med; 2003 Sep; 198(6):863-8. PubMed ID: 12963694
[TBL] [Abstract][Full Text] [Related]
7. Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis.
Zeng Y; Opeskin K; Goad J; Williams ED
Cancer Res; 2006 Oct; 66(19):9566-75. PubMed ID: 17018613
[TBL] [Abstract][Full Text] [Related]
8. Chimeric VEGF-E(NZ7)/PlGF promotes angiogenesis via VEGFR-2 without significant enhancement of vascular permeability and inflammation.
Zheng Y; Murakami M; Takahashi H; Yamauchi M; Kiba A; Yamaguchi S; Yabana N; Alitalo K; Shibuya M
Arterioscler Thromb Vasc Biol; 2006 Sep; 26(9):2019-26. PubMed ID: 16794222
[TBL] [Abstract][Full Text] [Related]
9. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses.
Rissanen TT; Markkanen JE; Gruchala M; Heikura T; Puranen A; Kettunen MI; Kholová I; Kauppinen RA; Achen MG; Stacker SA; Alitalo K; Ylä-Herttuala S
Circ Res; 2003 May; 92(10):1098-106. PubMed ID: 12714562
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins.
Karkkainen MJ; Haiko P; Sainio K; Partanen J; Taipale J; Petrova TV; Jeltsch M; Jackson DG; Talikka M; Rauvala H; Betsholtz C; Alitalo K
Nat Immunol; 2004 Jan; 5(1):74-80. PubMed ID: 14634646
[TBL] [Abstract][Full Text] [Related]
11. An engineered heparin-binding form of VEGF-E (hbVEGF-E). Biological effects in vitro and mobilizatiion of precursor cells.
Heil M; Mitnacht-Krauss R; Issbrücker K; van den Heuvel J; Dehio C; Schaper W; Clauss M; Weich HA
Angiogenesis; 2003; 6(3):201-11. PubMed ID: 15041796
[TBL] [Abstract][Full Text] [Related]
12. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice.
Veikkola T; Jussila L; Makinen T; Karpanen T; Jeltsch M; Petrova TV; Kubo H; Thurston G; McDonald DM; Achen MG; Stacker SA; Alitalo K
EMBO J; 2001 Mar; 20(6):1223-31. PubMed ID: 11250889
[TBL] [Abstract][Full Text] [Related]
13. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein.
Zhang D; Li B; Shi J; Zhao L; Zhang X; Wang C; Hou S; Qian W; Kou G; Wang H; Guo Y
Cancer Res; 2010 Mar; 70(6):2495-503. PubMed ID: 20197464
[TBL] [Abstract][Full Text] [Related]
14. Expression of VEGFR-3 and 5'-nase in regenerating lymphatic vessels of the cutaneous wound healing.
Ji RC; Miura M; Qu P; Kato S
Microsc Res Tech; 2004 Jun; 64(3):279-86. PubMed ID: 15452895
[TBL] [Abstract][Full Text] [Related]
15. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes.
Saaristo A; Veikkola T; Enholm B; Hytönen M; Arola J; Pajusola K; Turunen P; Jeltsch M; Karkkainen MJ; Kerjaschki D; Bueler H; Ylä-Herttuala S; Alitalo K
FASEB J; 2002 Jul; 16(9):1041-9. PubMed ID: 12087065
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis.
Björndahl MA; Cao R; Burton JB; Brakenhielm E; Religa P; Galter D; Wu L; Cao Y
Cancer Res; 2005 Oct; 65(20):9261-8. PubMed ID: 16230387
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype.
Issa A; Le TX; Shoushtari AN; Shields JD; Swartz MA
Cancer Res; 2009 Jan; 69(1):349-57. PubMed ID: 19118020
[TBL] [Abstract][Full Text] [Related]
18. Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer.
Jeon BH; Jang C; Han J; Kataru RP; Piao L; Jung K; Cha HJ; Schwendener RA; Jang KY; Kim KS; Alitalo K; Koh GY
Cancer Res; 2008 Feb; 68(4):1100-9. PubMed ID: 18281485
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical analysis of VEGF-C/VEGFR-3 system and lymphatic vessel extent in normal and adenomatous human pituitary tissues.
Onofri C; Losa M; Uhl E; Stalla GK; Renner U
Exp Clin Endocrinol Diabetes; 2008 Mar; 116(3):152-7. PubMed ID: 18205092
[TBL] [Abstract][Full Text] [Related]
20. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
Liu B; Ma J; Wang X; Su F; Li X; Yang S; Ma W; Zhang Y
Anat Rec (Hoboken); 2008 Oct; 291(10):1227-35. PubMed ID: 18561194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
